| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701783 | Journal of Thoracic Oncology | 2016 | 27 Pages |
Abstract
Compared with DOC, NIV is not cost-effective for the treatment of nonsquamous NSCLC at current prices in the Swiss health care setting. Price reduction or PD-L1 testing and selection of patients for NIV on the basis of test positivity improves cost-effectiveness compared with DOC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Klazien PhD, Matthias MPH, Stefan MD, Konstantin MD, Joachim MD, Mario Pietrini, Dirk PhD, Roger MD, Oliver MD, Swiss Group for Clinical Cancer Research Swiss Group for Clinical Cancer Research,